[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"borderline-personality-disorder-bpd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:borderline-personality-disorder-bpd":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,43,69,96,120,147,172,198,230,252,278,315,339,373,396,419,442],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100583769","affect-based-impulsivity-in-borderline-personality-disorder-100583769",false,"NCT06880640","Affect-based Impulsivity in Borderline Personality Disorder","Affect-based Impulsivity in Borderline Personality Disorder: Developing a Neurocomputational Phenotype","Inclusion Criteria:\n\nBorderline Personality Disorder (BPD) group:\n\n* Score of 38 or higher on Personality Assessment Inventory-Borderline Scale (PAI-BOR)\n* Participants in the BPD group will be primarily recruited from the two\n\nDEPENd lab studies that maintain large samples of BPD participants. To ensure maximal similarity between BPD participants recruited from other DEPENd lab studies and BPD participants recruited through other recruitment sources, the investigators will use the same criteria for the BPD group in the current study as the criteria used in the other DEPENd lab studies. BPD participants in the two DEPENd lab studies from which the investigators will be recruiting must meet the following criteria:\n\n1. 3+ BPD symptoms, one of which must be affective instability, per clinical interview\n2. Participants must score at least 80 on the Reynolds Intellectual Screening Test (RIST).\n\nHealth Control (HC) Group:\n\n* Score of 12 or lower on PAI-BOR\n* Score below 50th percentile on World Health Organization Disability Assessment Schedule (WHODAS)\n* Absence of any current or lifetime psychiatric disorder, including personality disorders as determined by diagnostic interviews (SIDP and SCID), if the participant had participated in the lab's other studies (IRB Nos. 20-1735 and 21-0602).\n\nCombined Inclusion Criteria:\n\n* Ages 18-45\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study\n* Willingness to participate in all components of the study\n* Participants must be able to speak, understand and read English.\n* Participants must have at least 20\u002F40 visual acuity (correct or uncorrected).\n\nExclusion Criteria:\n\n* Use of as needed antihypertensive agents within 12 hours prior to lab visit\n* Inability to refrain from using as needed psychotropic medications for 12 hours prior to lab visit\n* History of psychotic disorder, Bipolar I disorder, autism spectrum disorder, reactive attachment disorder, pervasive developmental disorder, motor disorder, head injury, mental retardation, neurological disorder, or current substance dependence\n* Family history of Bipolar I disorder in a first degree relative.\n* Participants are also excluded for any of the following: cardiac pacemaker, aneurysm clip, cochlear implants, pregnancy, shrapnel, history of metal fragments in eyes, neurostimulators, weight of 250 lbs. or more, or claustrophobia.",true,"ALL","18 Years","45 Years",{"count":21,"type":22},106,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of this research study is to investigate how personality traits and neuroendocrine systems relate to decision-making patterns in individuals 18-45 years old. The main question it aims to answer is how neuroendocrine activity impacts decision-making.\n\nParticipants will complete online behavioral tasks, a stress induction procedure, self-report surveys, and a cognitive assessment. During the session, psychophysiological measures will be collected, including electrocardiogram (ECG) and cardiac impedance (ICG) to monitor heart rate and blood flow, as well as electrodermal activity (EDA), blood drop samples, and saliva collection to assess nervous system activity.",[28,29],"Borderline Personality Disorder (BPD)","Healthy Controls Group - Age and Sex-matched","RECRUITING","2026-06-25",{"date":33,"type":34},"2026-06-26","ACTUAL",{"date":36,"type":34},"2025-09-21",{"date":38,"type":22},"2026-08",{"name":40,"class":41},"University of North Carolina, Chapel Hill","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":42},"100618920","conceptualizing-borderline-personality-disorder-as-a-relationship-use-disorder-100618920","NCT07337889","Conceptualizing Borderline Personality Disorder as a Relationship Use Disorder","TLUR","Inclusion Criteria:\n\n* General : aged 18-45\n* Specific :\n* Borderline personality disorder (BPD)assessed by SCID, without bipolar disorder\n* Bipolar disorder (assessed by SCID), without BPD (evaluated by SCID)\n* Healthy controls with no psychiatric disorders (screened by SCID).\n\nExclusion Criteria:\n\n* Psychotic disorders (evaluated by SCID)\n* lack of informed consent\n* Not affiliated with social security\n* Under judicial or administrative confinement or involuntary hospitalization\n* Protected by law (e.g., under guardianship)\n* Pregnancy or breastfeeding\n* Inability to understand, speak, or write in French\n* Inability to understand the study's purpose or methodology\n* Excluded from another study during the exclusion period\n* Participants who have received over €6000 in annual indemnities\n* For Bipolar Participants (without BPD) : Current moderate or severe depressive episode (BDI score \\> 18) or Current hypomanic\u002Fmanic episode (YMRS \\\u003C 12)",{"count":51,"type":22},194,[25],"This study aims to explore a novel conceptualization of Borderline Personality Disorder (BPD) as a \"Relationship Use Disorder.\" The research proposes that BPD shares key features with behavioral addictions, specifically addiction to interpersonal relationships. The study builds upon previous findings suggesting that individuals with BPD experience intense emotional dysregulation, including negative self-perception, shame, and a compulsive need for external validation. This addiction to relationships, much like substance use disorders, is thought to contribute significantly to the difficulties faced by these individuals, including interpersonal conflicts, self-destructive behaviors, and emotional instability.\n\nThe study seeks to demonstrate that the relational difficulties central to BPD meet the diagnostic criteria for addiction as defined by the DSM-5. It will also explore how these relational struggles are mediated by dysfunctional self-perception and whether they are linked to behaviors such as compulsive sexual behaviors (CSBD) or suicidal tendencies. Additionally, the research will investigate the relationship between addiction to relationships and neurobiological factors, including endorphin levels, in individuals with BPD compared to those with bipolar disorder and healthy controls. The hypothesis is that individuals with BPD will exhibit higher levels of relationship addiction, with this addiction being tied to their perception of self-worth and emotional experiences in relationships.\n\nThis innovative approach aims to refine the understanding of BPD, reduce stigma, and improve treatment strategies by providing scientific evidence supporting the conceptualization of BPD as a \"Relationship Use Disorder.\"",[55,28,56],"Borderline Personality Disorder","Bipolar Disorder (BD)",[58,59],"borderline personality disorder","relationship-use disorder","2026-06-18",{"date":62,"type":34},"2026-06-22",{"date":64,"type":34},"2026-06-01",{"date":66,"type":22},"2028-08-01",{"name":68,"class":41},"University Hospital, Montpellier",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":42},"100642393","the-role-of-gender-in-borderline-personality-disorder-100642393","NCT07639957","The Role of Gender in Borderline Personality Disorder","What Role Does Gender Play in Relationship and Self Experiences of Individuals With Borderline Personality Disorder?","BPD-G","Inclusion Criteria:\n\n1. Signed informed consent form\n2. Individuals of all genders (target: n=5 with female gender identity, n=5 with nonbinary\u002Ftrans\\*\u002Fgender-non-conforming (TGNC) gender identity, n=5 with male gender identity) between the ages of 18 and 65 at the time of consent\n3. Individuals with a BPD diagnosis made within the last 2 years (ICD-10: F60.3; DSM-5: 301.83, ICD-11: Borderline qualifier)\n4. Understanding of the study procedure, ability and willingness to participate\n5. The participant is able to read and understand the informed consent form and can provide a written, personally signed, and dated informed consent form.\n\nExclusion Criteria:\n\n1. Acute suicidal ideation or acute psychotic symptoms reported by the patient or suspected\n2. Insufficient language skills (i.e., knowledge of German or English)","65 Years",{"count":79,"type":22},15,"OBSERVATIONAL","This study is a mixed-methods, single-arm cross-sectional study comprising 1) a qualitative, exploratory, critical-constructivist content analysis examining the significance of gender in relationship experiences and self-perception among individuals with borderline personality disorder and various gender identities, and 2) a pilot study on the use of the Single-Category Implicit Association Test (SC-IATs, adapted from von Hippel et al., 2018) as preparation for a larger-scale experimental psychological study using the SC-IAT to assess implicit gender- and BPD-related thought processes in people with borderline personality disorder and various gender identities.\n\n15 individuals with BPD and different gender identities will be assessed. The research questions are:\n\n1. What gender-related relationship- and self-experiences can be identified in people with BPD? How do experiences relate to observer-coded and self-reported mentalization ability, as well as self-reported symptoms, experiences of stigmatization, and quality of life?\n2. Is there preliminary evidence that Single-Category Implicit Association Tests (SC-IATs) are suitable and reliable instruments for measuring implicit gender- and BPD-related thought processes in people with BPD?",[28],[55,84,85,86],"Gender","Grounded Theory","Implicit Association Test","2026-06-07",{"date":89,"type":34},"2026-06-10",{"date":91,"type":22},"2026-05-29",{"date":93,"type":22},"2027-03-31",{"name":95,"class":41},"University Hospital Heidelberg",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":23,"phases":106,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":42},"100628385","phase-1-a-pilot-trial-of-one-day-accelerated-tms-and-d-cycloserine-in-suicidal-patients-with-borderline-personality-disorder-100628385","NCT07460947","A Pilot Trial of One-Day Accelerated TMS and D-cycloserine in Suicidal Patients With Borderline Personality Disorder","A Pilot Trial of One Day Accelerated Intermittent Theta-burst Stimulation Plus D-cycloserine in Suicidal Patients With Borderline Personality Disorder (ONE-D BPD)","ONE-D BPD","Inclusion Criteria:\n\n* Adult (18+) of any gender\n* Meets DSM-5 criteria for BPD, per assessment with the Structured Clinic Interview for DSM-5 Personality Disorders (SCID-5-PD), BPD Module\n* Moderate to severe SI during the two weeks prior to screening, as indexed by a score of 9 or higher on the Modified Scale for Suicide Ideation - Self Report (Clum \\& Yang, 1995)\n\nExclusion Criteria:\n\n* Current manic or hypomanic symptoms, as assessed by the Diagnostic Assessment Research Tool (DART) screener and diagnostic modules, where relevant.\n* Current clinically significant psychotic symptoms not better accounted for by BPD, as assessed by the DART psychotic symptoms screener.\n* Current alcohol or substance use disorder, that in the opinion of a study PIs, is of sufficient severity to impede engagement in treatment or is associated with significant risk of medical withdrawal, as assessed by the DART.\n* Medical documentation or self-report of current anorexia nervosa, bulimia nervosa, or eating disorder not otherwise specified - atypical anorexia nervosa or atypical bulimia nervosa, that is in the opinion of a study PIs is of sufficient severity to be associated with significant medical risks\n* Acute suicide risk, sufficient to require immediate hospitalization;\n* history of traumatic brain injury (TBI) or concussion involving loss of consciousness or amnesia for ≥24 hours;\n* any significant neurological disorder likely to be associated with increased intracranial pressure or cognitive impairment (e.g., epilepsy; Parkinson's disease);\n* diagnosed neurodevelopmental disorder (e.g., autism, downs syndrome; Ehlers-Danlos Syndrome) other than attention-deficit hyperactivity disorder (ADHD) or dyslexia\n* current diagnosis of delirium or dementia;\n* cognitive disorder secondary to a general medical condition\n* Pregnant and breastfeeding people are excluded in line with the studies our protocol is based upon using DCS and aTMS. Assessment of pregnancy will be completed during the 1-week prior to the administration of DCS (i.e., taken the night before TMS treatment), where relevant and according to MGB IRB policy.\n* Participants with contraindications to TMS (e.g., metal in head or neck area), or at increased risk for adverse events (e.g., seizure history or markedly heightened risk factors for seizures, serious medical problems, implanted devices) will be excluded.\n* Participants with a known allergy to DCS will be excluded from the study.\n* No patients with involuntary hospitalization status will be recruited for the study.\n* No individuals who are not proficient in English will be recruited for the study\n* Subject does not have a PCP",{"count":105,"type":22},20,[107,108],"PHASE1","PHASE2","This study tests a new treatment for people with borderline personality disorder (BPD). The treatment combines a medication called D-cycloserine with one day of transcranial magnetic stimulation (TMS).\n\nThe main questions it aims to answer are:\n\n* How many participants complete the treatment?\n* How do participants feel about the treatment?\n* Does the treatment have neurophysiological changes on participants?\n* Does the treatment improve BPD symptoms?\n* Do the benefits last over time?\n\nParticipants will be asked to:\n\n* Come to the clinic for interviews and testing\n* Complete weekly questionnaires for 4 weeks before the treatment day\n* Take D-cycloserine the night before treatment\n* Attend one treatment day at the clinic. On that day, they may receive up to 20 short TMS sessions (each lasting 3 minutes and separated by 30 minutes). This visit may last up to 12 hours.\n* Complete weekly questionnaires for 6 weeks after the treatment day.",[28],"2026-06-02",{"date":113,"type":34},"2026-06-04",{"date":115,"type":22},"2026-06-09",{"date":117,"type":22},"2027-12",{"name":119,"class":41},"Mclean Hospital",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":16,"sex":128,"minAge":18,"maxAge":19,"enrollmentInfo":129,"targetDuration":4,"studyType":23,"phases":131,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":4},"100583055","perimenstrual-symptoms-and-emotional-dysregulation-in-autism-100583055","NCT06871345","Perimenstrual Symptoms and Emotional Dysregulation in Autism","Evaluation of the Links Between Perimenstrual Symptoms and Emotional Dysregulation in Autistic Individuals: Ecological, Subjective, and Cognitive Approach","MEDEA","Inclusion criteria:\n\nCommon Inclusion Criteria for Healthy Patients and Volunteers:\n\n* Female aged 18 to 45;\n* Woman with regular menstrual cycles (variations in duration, measured between the shortest menstrual cycle) and the longest cycle, remain strictly less than 7 days) between 25 and 35 days;\n* Woman without hormonal contraception (or NON-hormonal copper IUD) or who has stopped contraception for more than 3 months (and does not wish to take it again);\n* Woman with a smartphone with an internet connection;\n* Woman able to understand the objectives and risks of the research and to give informed, dated and signed consent;\n* Woman affiliated to a social protection health insurance scheme, beneficiary or beneficiary.\n\nPatient-specific inclusion criteria:\n\n* Specific inclusion criteria for female patients\n* Patient with a diagnosis of Autism Spectrum Disorder without intellectual disability (ASD), according to DSM-5 criteria OR\n* Patient with a diagnosis of BPD, according to DSM-5 criteria OR\n* Patient meeting the diagnostic criteria for PMDD with the SCID\n\nExclusion criteria:\n\nNon-inclusion criteria common to healthy patients and volunteers:\n\n* Taking hormonal treatment or synthetic steroids;\n* Woman using hormonal contraceptives (pill, patch, hormonal IUD, vaginal ring, implant, intramuscular injection);\n* Pregnancy or breastfeeding on the declaration of the person for less than 3 months;\n* Desire to become pregnant within 3 months of inclusion;\n* Endocrinopathies (in particular clinical signs of hyperandrogenism) or untreated gynaecological pathologies that may influence menstrual cycles and\u002For ovulation;\n* Participation in another study that may interfere with the study;\n* Inability to give the person informed information (person in an emergency or life-threatening situation);\n* Woman under judicial protection;\n* Woman under guardianship or curatorship;\n* Woman hospitalized for a period \\> 24 hours\n\nPatient-specific non-inclusion criteria:\n\n* Patient with a diagnosis of psychotic disorder;\n* Patient with a diagnosis of severe substance use disorder, i.e., presence of 6 or more symptoms;\n* Patient with a diagnosis of bipolar disorder type I or II or cyclothymia;\n* Patient with a diagnosis of co-occurring ASD and BPD;\n* Patient with an intellectual disability (IQ ≤ 70);\n* Patient with neurological comorbidity (e.g., acquired brain injury);\n* Patient on treatment that alters physiological response (heart rhythm, e.g., beta-blockers).\n\nNon-inclusion criteria specific to healthy volunteers:\n\n\\- Woman with a psychiatric, neurodevelopmental, or neurological history;","FEMALE",{"count":130,"type":22},90,[25],"Emotional dysregulation (ED) is defined by difficulties in modulating the experience and expression of emotions, which are characterized by particularly marked reactivity, intensity, and duration. To improve the understanding of ED, its consequences in autistic women, and to be able to offer them appropriate treatments, it seems crucial to investigate the links between ED, known adversities during childhood, and premenstrual dysphoric symptoms. This study aims to characterize the variability of ED throughout a menstrual cycle by measuring it in an ecological real-life context. The variability of ED will be compared to that of women with borderline personality disorder (BPD), women with premenstrual dysphoric disorder (PMDD), and women without a diagnosed disorder.",[134,135,136],"Autism Spectrum Disorder","Borderline Personality Disorder BPD","a Premenstrual Dysphoric Disorder (PMDD)","NOT_YET_RECRUITING","2026-05-11",{"date":140,"type":34},"2026-05-12",{"date":142,"type":22},"2026-05-01",{"date":144,"type":22},"2029-07-01",{"name":146,"class":41},"University Hospital, Strasbourg, France",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":77,"enrollmentInfo":155,"targetDuration":4,"studyType":23,"phases":157,"briefSummary":158,"conditions":159,"keywords":161,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":42},"100600595","phase-2-ketamine-infusion-for-symptomatic-improvement-in-severe-borderline-personality-disorder-100600595","NCT07099534","Ketamine Infusion for Symptomatic Improvement in Severe Borderline Personality Disorder","Ketamine Infusion for Symptomatic Improvement in Severe Borderline Personality Disorder: A Pilot Study","BorderKET","Inclusion Criteria:\n\n* Adult patient aged 18 to 65 years\n* Fluent in French\n* Person affiliated with or receiving social security benefits.\n* Diagnosis of borderline personality disorder established according to the DSM-5 MINI criteria (5 out of 9 criteria)\n* Severe borderline personality disorder\n* Patient receiving stable pharmacological (antipsychotic, mood stabilizer, antidepressant) and\u002For non-pharmacological (schema therapy, DBT) treatment for four weeks\n\nExclusion Criteria:\n\n* Personal history of an acute psychotic episode or chronic psychotic disorder\n* Personal history of a manic or hypomanic episode\n* Family history (first-degree relatives) of a psychotic disorder\n* Current severe depressive episode\n* Recreational ketamine use (multi-weekly ketamine use)\n* New long-term treatment introduced within the previous four weeks (antidepressant, antipsychotic, mood stabilizer)\n* Prescription of an Monoamine oxidase inhibitors (increased risk of hypertension)\n* Specific absolute contraindication to ketamine\n* History of cirrhosis or major liver function test abnormalities\n* Major ECG abnormality",{"count":156,"type":22},38,[108],"The main objective of this pilot study is to evaluate at D9 the evolution of BPD symptoms' intensity(scale BSL-23) in severe BPD patients, after two Ketamine infusions (0.5mg\u002Fkg at H0 and H24). The intervention is combined with the first level standard of care : Good Psychiatric Management (GPM). Patients are followed up to 3 months by regular visits conducted by a psychiatrist. Secondary outcomes are monitored including BPD symptoms at different times, suicidal ideation, depressiv symptoms, healthcare use and adverse effects.",[160,28],"Infusion of Ketamine in Severe Borderline Personality Disorder",[162,58,163],"Ketamine","BDP","2026-05-07",{"date":140,"type":34},{"date":167,"type":22},"2026-09-01",{"date":169,"type":22},"2028-09-30",{"name":171,"class":41},"University Hospital, Toulouse",{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":77,"enrollmentInfo":178,"targetDuration":4,"studyType":23,"phases":180,"briefSummary":181,"conditions":182,"keywords":184,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":42},"100640452","extended-group-written-exposure-therapy-for-comorbid-ptsd-and-bpd-traits-100640452","NCT07576387","Extended Group Written Exposure Therapy for Comorbid PTSD and BPD (Traits)","Inclusion Criteria:\n\n* Reading and writing proficiency in English\n* Access to an electronic device to attend virtual group meetings\n* Age 18-65\n* Previous diagnosis of Posttraumatic Stress Disorder (PTSD) and Borderline Personality Disorder (BPD)\u002FBPD traits\n* Completion of a DBT skills group via St. Joe's Community Psychiatry Clinic\n\nExclusion Criteria:\n\n* Diagnosis of an active severe substance use disorder or psychotic disorder\n* Untreated active psychotic symptoms, mania, or hypomania\n* Has attempted suicide in the 2 months prior to treatment beginning\n* Has engaged in high-risk self-harm (e.g., cutting, burning, asphyxiation) in the 2 months prior to beginning treatment\n* Has completed Cognitive Processing Therapy or another active PTSD treatment (i.e., prolonged exposure) in the past year",{"count":179,"type":22},63,[25],"The goal of this open label trial is to evaluate the effectiveness of virtual group extended Written Exposure Therapy (GE-WET) in reducing Post-Traumatic Stress Disorder (PTSD) symptoms in patients with comorbid PTSD and Borderline Personality Disorder (BPD) or BPD traits. GE-WET involves attending weekly 2-hour group WET sessions for the duration of 10 weeks, in which they write about their trauma experience using specific instructions.\n\nThis study will be conducted at St. Joseph's Healthcare Hamilton's Community Psychiatry Clinic with clients wait listed for PTSD treatment (ages 18- 65, any gender, co-morbid PTSD and BPD\u002FBPD traits).\n\nThe main questions this study aims to answer are:\n\nDoes GE-WET reduce PTSD symptoms (based on PCL-5 measures) in this population (outpatient clients ages 18-65 of any gender, with a diagnosis of PTSD and BPD or BPD traits)?\n\nDoes GE-WET result in reduced drop-out rates for this population, compared to that of other evidence-based treatment for PTSD?\n\nWhat are participants subjective experience of GE-WET?",[183,28],"Posttraumatic Stress Disorder (PTSD)",[58,185,186,187,188],"posttraumatic stress disorder","written exposure therapy","group therapy","virtual","2026-05-04",{"date":191,"type":34},"2026-05-08",{"date":193,"type":22},"2026-06",{"date":195,"type":22},"2028-12",{"name":197,"class":41},"St. Joseph's Healthcare Hamilton",{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":206,"enrollmentInfo":207,"targetDuration":4,"studyType":23,"phases":209,"briefSummary":210,"conditions":211,"keywords":217,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":226,"leadSponsor":228,"locationsCount":4},"100636708","phase-2-ketamine-with-dialectical-behavioural-therapy-dbt-for-suicidality-in-individuals-with-treatment-resistant-depression-and-borderline-personality-disorder-ket-dbt-100636708","NCT07569198","Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT)","Combining Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder: A Phase II Randomized, Midazolam-Controlled Clinical Trial (KET-DBT)","KET-DBT","Inclusion Criteria:\n\n1. Adults between the age of 18 to 70, inclusive;\n2. Meets criteria for BPD, as determined by clinical assessment by a psychiatrist or psychologist and confirmed by the International Personality Disorder Examination (IPDE);\n3. Meets DSM-5 criteria for MDD or BD (I or II), currently experiencing a MDE without psychotic features, as diagnosed by a study psychiatrist or psychologist. Diagnosis will be confirmed using the Mini- International Neuropsychiatric Interview (MINI);\n4. Current MDE must be moderate to severe, as determined by the MADRS score \\>20 with an inadequate response to two or more guideline-concordant treatment trials as defined by the Antidepressant Treatment History Form-Short Form (ATHF- SF);\n5. No changes in pharmacotherapy for MDD\u002FBD in the last month or changes in psychotherapy in the past month;\n6. Baseline SI as shown by two consecutive MSSI scores \\> 10 two weeks apart.\n\nExclusion Criteria:\n\n1. Past or current history of a psychotic disorder as determined by clinical assessment and MINI;\n2. Current or recent (within the past 3 months) manic or hypomanic episode as determined by clinical assessment via YMRS (score \\> 12) and the MINI;\n3. Meeting criteria for Moderate to Severe Alcohol or substance use disorders currently or within the past 3 months;\n4. Lifetime history of ketamine use disorder or illicit ketamine use.\n5. Acute suicide risk requiring involuntary inpatient treatment under the Mental Health Act (MHA).\n6. Presence of a relative or absolute contraindication to ketamine or midazolam, including a drug allergy, lifetime history of stroke, uncontrolled hypertension (Systolic BP \\> 160 or Diastolic BP \\> 100), low or labile blood pressure (Systolic BP \\\u003C 100 or Diastolic BP \\\u003C 60), recent (within the past 6 months) myocardial infarction, severe coronary artery disease (ascertained through participant's medical history), or moderate to severe renal (GFR scores ≤ 44) or hepatic impairment (A Child-Pugh score of ≥ 7);\n7. Currently pregnant or breastfeeding or planning on getting pregnant within the first two months of the trial or planning on getting someone else pregnant within the first two months of trial. Participants who are sexually active must agree to use a highly effective contraceptive method (please see exhaustive list in Section 3.6.1);\n8. Current use of prohibited concomitant medications, including other forms of ketamine or esketamine, high dose daily benzodiazepines (greater than 4 mg lorazepam equivalent daily) or monoamine oxidase inhibitors;\n9. Currently engaged (or completed within the past year) in DBT treatment. NOTE: Individuals who have received only DBT skills training in the past year will be considered eligible to participate;\n10. Those engaged in other forms of psychotherapy must be willing to discontinue for the duration of the 6-month DBT intervention (standard for DBT). There should be no changes in psychotherapy 30 days prior to baseline (i.e., Screening Visit 2).","70 Years",{"count":208,"type":22},120,[108],"The goal of this clinical trial is to learn if intravenous (IV) ketamine with Dialectical Behavioural Therapy (DBT) reduces suicidal ideation in individuals with suicidality who have been diagnosed with Borderline Personality Disorder and either Major Depressive Disorder or Bipolar Disorder. The main question it aims to answer is:\n\nDoes IV ketamine and DBT produce more rapid and robust improvements in suicidal ideation (SI) severity between baseline and Day 35 compared to IV midazolam and DBT, as measured by changes in the Modified Scale for Suicidal Ideation (MSSI) scores ?\n\nResearchers will compare six IV ketamine infusions and DBT to an active placebo (a look-alike substance that mimics some of ketamine's effects and not others) and DBT to see if IV ketamine with DBT is more effective at reducing SI severity.\n\nParticipants will:\n\n* Complete six infusions of either IV ketamine or IV midazolam\n* Take part in 6 months of DBT (includes both weekly one-on-one sessions, and group sessions, starting week 5 of the trial)\n* Visit the hospital for scheduled in-person visits\n* Join a call or videocall for scheduled remote visits\n* Complete a variety of different mood, cognitive and behavioral assessments",[28,212,213,214,56,215,216],"Treatment-Resistant Major Depressive Disorder","Treatment-resistant Bipolar Depression","Major Depressive Disorder (MDD)","Bipolar Disorder I or II","Suicidal Ideation",[218,219,55,220,56,214,221],"Dialectical Behavioural Therapy (DBT)","ketamine","Treatment-Resistant Depression","Suicidality","2026-04-28",{"date":224,"type":34},"2026-05-06",{"date":64,"type":22},{"date":227,"type":22},"2029-08",{"name":229,"class":41},"Joshua Rosenblat",{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":237,"enrollmentInfo":238,"targetDuration":4,"studyType":23,"phases":240,"briefSummary":241,"conditions":242,"keywords":4,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":42},"100625866","characterization-of-the-neural-bases-of-mental-imagery-in-individuals-with-borderline-personality-disorder-an-eeg-study-100625866","NCT07428200","Characterization of the Neural Bases of Mental Imagery in Individuals With Borderline Personality Disorder: An EEG Study","BABO","Inclusion Criteria:\n\n* For patients, a diagnosis of borderline personality disorder (established by a board-certified psychiatrist during a structured interview using the MINI) based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)\n* For healthy individuals, no psychiatric disorders according to the DSM-5 (except for tobacco use)\n* Must be between 18 and 40 years old\n* Must provide a signed, free, and informed consent form\n* To be affiliated with a social security scheme in France or to be a beneficiary of such a scheme\n\nExclusion Criteria:\n\n* Known neurological disorders (patient group and control participants)\n* Comorbid psychiatric disorders (e.g., current depressive episode; ADHD treated with methylphenidate; bipolar disorder)\n* Active substance use disorder (excluding tobacco)\n* Pregnancy or breastfeeding\n* Guardianship\n* Consuming more than three alcoholic drinks in the past 24 hours\n* Consuming alcohol on the day of the experiment\n* Consuming tea or coffee less than one hour before the experiment","40 Years",{"count":239,"type":22},62,[25],"Borderline Personality Disorder (BPD) involves altered social cognition, notably dysfunctional processing of cues signaling potential social exclusion and heightened social pain. This study uses EEG during a controlled Cyberball task to test whether BPD patients show a functionally altered social-pain network, particularly increased theta activity, when experiencing induced social exclusion.",[135],"2026-02-17",{"date":245,"type":34},"2026-02-23",{"date":247,"type":22},"2026-03-01",{"date":249,"type":22},"2029-03-01",{"name":251,"class":41},"Hôpital le Vinatier",{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":77,"enrollmentInfo":260,"targetDuration":4,"studyType":23,"phases":262,"briefSummary":263,"conditions":264,"keywords":266,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":274,"leadSponsor":276,"locationsCount":42},"100616403","pilot-study-for-the-evaluation-of-a-new-psychotherapeutic-treatment-for-borderline-personality-disorder-patients-with-post-traumatic-stress-symptoms-100616403","NCT07305155","Pilot Study for the Evaluation of a New Psychotherapeutic Treatment for Borderline Personality Disorder Patients With Post-traumatic Stress Symptoms","A Feasibility Randomized-controlled Trial Comparing Trauma-focused Mentalization Based Treatment With Standard Mentalization-based Treatment in Patients Presenting With Complex Post-traumatic Stress and Borderline Personality Disorder","MBT-TF","Inclusion Criteria:\n\n* Age between 18 and 65 years.\n* Meeting ≥4 of 9 SCID-5 PD criteria associated with functional impairment (either subthreshold or full BPD diagnosis), and an LPFS-BF 2.0 score ≥31 (≥1.5 standard deviations above the latent mean, T-score ≥65), indicating moderate to severe personality disorder features.\n* Diagnosis of CPTSD according to ICD-11 criteria, confirmed via ITQ with clinical checks.\n\nExclusion Criteria:\n\n* Mental disability.\n* Severe psychiatric psychopathology requiring immediate treatment (e.g., BMI \\\u003C16.5, acute bipolar episode, current psychosis).\n* Severe active substance dependence.\n* Severe physical health problems (e.g., severe cardiovascular conditions). Severe neurological disorder.",{"count":261,"type":22},40,[25],"Borderline Personality Disorder (BPD) is a serious mental health condition that often co-occurs with Complex PTSD (CPTSD), making treatment more challenging. Trauma-Focused Mentalization-Based Treatment (MBT-TF) is a new adaptation of standard MBT designed for individuals with high trauma exposure. Early findings are promising, but further research is needed. This study at Geneva University Hospitals (HUG) will test the feasibility and acceptability of MBT-TF compared with standard MBT, gathering feedback from patients and clinicians and laying the groundwork for a larger clinical trial.",[28,265],"PTSD - Post Traumatic Stress Disorder",[55,267,268,269],"Post Traumatic Stress Disorder","Mentalization-based treatment","trauma-focused mentalization-based treatment","2026-02-04",{"date":272,"type":34},"2026-02-06",{"date":64,"type":22},{"date":275,"type":22},"2030-12",{"name":277,"class":41},"Eva Rüfenacht",{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":284,"eligibilityCriteria":285,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":286,"targetDuration":4,"studyType":23,"phases":288,"briefSummary":289,"conditions":290,"keywords":292,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":314},"100619193","physical-activity-in-the-management-of-personality-disorders-100619193","NCT07341438","Physical Activity in the Management of Personality Disorders","Physical Activity in the Management of Personality Disorders: Protocol for a Three-Arm Randomized Feasibility Trial (The PANDA Trial)","PANDA","Inclusion Criteria:\n\n* adults (≥18 years)\n* documented diagnosis of borderline personality disorder (BPD; F60.3, ICD-10) or avoidant personality disorder (AVPD; F60.6, ICD-10), as confirmed in the patient's medical record.\n* at the time of recruitment, participants must be receiving treatment at one of two specialized psychotherapeutic outpatient clinics (Clinic A or Clinic B) in the Capital Region of Denmark\n* proficient in Danish.\n\nExclusion Criteria:\n\n* Individuals with a documented diagnosis of antisocial personality disorder (F60.2)",{"count":287,"type":22},60,[25],"The PANDA trial is studying whether two types of physical activity - a walking program and supervised karate training - are safe, acceptable, and possible for adults with certain personality disorders. The goal is to see if these activities can help people while being safe and easy to do.\n\nWho can take part:\n\n* Adults with borderline personality disorder or avoidant\u002Fanxious personality disorder.\n* People receiving treatment at two outpatient mental health clinics in the Capital Region of Denmark.\n* The study plans to include about 60 participants.\n\nWhat will happen in the study:\n\nParticipants are randomly assigned to one of three groups:\n\n* Usual treatment only (control group).\n* Usual treatment plus walking program: an 8 - week pedometer - based program with goal setting and follow-up sessions.\n* Usual treatment plus supervised karate training: an 8 - week program led by experienced instructors.\n\nWhat the study will look at:\n\n* Main goal: Check if the programs can be done as planned, including whether participants attend sessions, follow the program, and stay safe.\n* Other outcomes: Possible changes in physical health, fitness, emotions, personality symptoms, body image, and daily activity.\n* Data will be collected through physical tests, questionnaires, and follow-up interviews about participants' experiences and motivation.\n* Measurements will take place at the start, after 8 weeks, and after 12 weeks (follow-up questionnaires only).\n\nWhy this study is important:\n\nThe results will help researchers decide if it is possible to run a larger study in the future to see if walking or karate training can improve health and wellbeing for people with personality disorders.",[28,291],"Avoidant Personality Disorders",[293,294,295,296,297,298,299,58,300,301,302,303,304],"Physical activity","karate","walking","pedometer","martial arts","psychiatry","personality disorders","avoidant personality disorder","feasibility","rct","randomized controlled trial","exercise","2026-02-02",{"date":307,"type":34},"2026-02-03",{"date":309,"type":22},"2026-02-01",{"date":311,"type":22},"2026-12-01",{"name":313,"class":41},"Julie Midtgaard",2,{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":321,"eligibilityCriteria":322,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":323,"targetDuration":4,"studyType":23,"phases":324,"briefSummary":325,"conditions":326,"keywords":327,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":337,"locationsCount":42},"100619306","internal-family-systems-therapy-for-borderline-personality-disorder-100619306","NCT07342907","Internal Family Systems Therapy for Borderline Personality Disorder","Effectiveness of Internal Family Systems Therapy in Improving Mental Health in Individuals With Borderline Personality Disorder","IFS for BPD","Inclusion Criteria:\n\n* Resident of Ontario, Canada;\n* Sufficient fluency in English to provide informed consent, participate in therapy sessions, and complete self-reported assessments;\n* Diagnosis of borderline personality disorder confirmed by a healthcare professional authorized to establish such a diagnosis in Ontario;\n* Willingness and ability (including financial means) to participate in the 50-session, 12-15-month intervention and the study assessments;\n* Capacity and willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Current manic or psychotic symptoms regardless of diagnosis;\n* Substance dependence severe enough to interfere with meaningful level of engagement in the study intervention.\n* Cognitive impairment or neurological disorders that would preclude informed consent or meaningful participation in the study intervention.\n* Concurrent participation in any another form of psychotherapy.",{"count":79,"type":22},[25],"Borderline Personality Disorder (BPD) involves intense emotional ups and downs, unstable relationships, impulsivity, and a poor sense of self. These challenges often lead to addiction, self-harm, and frequent use of healthcare services. While certain treatments already in practice - such as dialectical behavior therapy - can help, they don't work for everyone or address all aspects of the disorder. This study plans to explore internal family systems (IFS) therapy, a method that views the mind as made up of different \"parts\" - each with its own thoughts and feelings. IFS helps people build understanding and compassion toward these parts and connect with a calmer, more centered \"Self.\" This may be especially useful for those with BPD, who often feel fragmented and extremely critical of themselves and others. This will be the first study to examine internal family systems therapy for BPD. The participants (15 in total) will receive up to 50 individual sessions over 15 months. Changes in symptoms and overall mental health will be measured at four points during the study. People with lived experience of BPD will help shape the research to ensure it is relevant, respectful, and useful for others facing similar challenges.",[28],[58,328,329,330],"psychotherapy","effectiveness","internal family systems therapy","2026-01-14",{"date":333,"type":34},"2026-01-16",{"date":335,"type":22},"2026-02",{"date":195,"type":22},{"name":338,"class":41},"Waypoint Centre for Mental Health Care",{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":4,"eligibilityCriteria":345,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":346,"targetDuration":4,"studyType":23,"phases":348,"briefSummary":349,"conditions":350,"keywords":356,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":42},"100611344","culturally-adapted-dialectical-behavior-therapy-for-low-middle-income-countries-100611344","NCT07239362","CULTURALLY ADAPTED DIALECTICAL BEHAVIOR THERAPY FOR LOW-MIDDLE-INCOME COUNTRIES","Culturally Adapted Dialectical Behavior Therapy (DBT) for Mental Health in LMICs: A Randomized Controlled Trial (RCT)","Inclusion Criteria:\n\n* Adults aged 18-45 years\n* Adults who are diagnosed with or have significant traits of borderline personality disorder (BPD)\n* Adults who are willing to provide written informed consent\n\nExclusion Criteria:\n\n* Severe psychiatric comorbidity (e.g., active psychosis, substance use, etc.)\n* Acute medical conditions interfering with participation\n* Lack of basic reading and writing, or any learning disability",{"count":347,"type":22},220,[25],"The study aims to assess the efficacy of culturally adapted dialectical behaviour therapy (DBT) for addressing emotional dysregulation in a low- and middle-income country, as well as to evaluate the impact of DBT on secondary outcomes such as borderline personality traits, self-harm or suicide, depression, anxiety, and individuals' functioning and disability.\n\nThrough a rigorous Randomised Controlled Trial (RCT), the research seeks to assess how cultural adaptations of dialectical behaviour therapy improve its applicability, engagement, and outcomes in diverse socio-cultural settings, contributing to more accessible and effective mental health interventions in resource-limited regions.",[28,351,352,353,354,355],"Dialectical Behavior Therapy","Emotional Dysregulation","Self Harm","Suicidal and Self-injurious Behavior","Depression Anxiety Disorder",[357,358,359,360,361,362,363],"BPD","DBT","Self harm","Suicide","Borderline personality","Dialectical behavior therapy","Emotional dysregulation","2025-11-22",{"date":366,"type":34},"2025-11-28",{"date":368,"type":22},"2025-11-20",{"date":370,"type":22},"2026-07-31",{"name":372,"class":41},"Pakistan Association of Cognitive Therapists",{"id":374,"slug":375,"hasResults":11,"nctId":376,"briefTitle":377,"officialTitle":377,"acronym":378,"eligibilityCriteria":379,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":380,"targetDuration":4,"studyType":23,"phases":382,"briefSummary":383,"conditions":384,"keywords":385,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":4},"100608254","effectiveness-of-autobiographical-rewriting-workshops-on-the-socio-professional-functioning-of-patients-with-borderline-personality-disorder-undergoing-third-wave-cognitive-and-behavioral-therapy-a-randomized-controlled-trial-100608254","NCT07199166","Effectiveness of Autobiographical Rewriting Workshops on the Socio-Professional Functioning of Patients With Borderline Personality Disorder Undergoing Third-Wave Cognitive and Behavioral Therapy: A Randomized Controlled Trial","ICS","Inclusion Criteria:\n\n* Subjects with borderline personality disorder (assessed by SCID-2),\n* Subjects aged between 18 and 45 years (inclusive).\n\nExclusion Criteria:\n\n* Psychotic disorder (assessed by SCID),\n* Subjects deprived of their liberty (by judicial or administrative decision, or involuntary hospitalization),\n* Subjects under legal protection (guardianship, curatorship, or judicial protection),\n* Subjects not affiliated with a social security,\n* Pregnant or breastfeeding women,\n* Inability to understand the nature, purpose, and methodology of the study,\n* Inability to understand, speak, or write French,\n* Failure to provide informed oral consent to participate in the study.",{"count":381,"type":22},140,[25],"This study evaluates the effectiveness of autobiographical rewriting workshops combined with third-wave Cognitive Behavioral Therapy (CBT) in improving social and professional functioning in individuals with Borderline Personality Disorder (BPD). BPD affects approximately 2 to 6% of the general population and is frequently associated with suicidal behaviors, unstable relationships, and low self-esteem. This disorder is often linked to early traumatic experiences that impact autobiographical memory and self-perception. While Dialectical Behavioral Therapy (DBT) is a standard treatment for BPD, it does not fully address all the needs of patients.\n\nThe aim of this study is to determine whether autobiographical rewriting, which allows individuals to restructure and reinterpret their memories in a more resilient way, can improve autobiographical memory, self-esteem, and reduce emotional symptoms. Participants will be randomized into two groups: one group will undergo autobiographical rewriting workshops in addition to third-wave CBT sessions, while the other group will participate in non-specific writing sessions also in addition to third-wave CBT sessions. The study will compare the two groups to evaluate the effectiveness of autobiographical rewriting workshops in enhancing social and professional well-being.\n\nExpected outcomes include improvements in interpersonal relationships, greater professional stability, and a reduction in emotional symptoms assessed immediately post-intervention, then 3 months and 6 months after. This study may offer a complementary therapeutic approach to existing treatments, helping patients manage their symptoms more effectively and improve their quality of life.",[55,28],[58,386,387],"autobiographical rewriting","third wave CBT","2025-09-22",{"date":390,"type":34},"2025-09-30",{"date":392,"type":22},"2025-10-01",{"date":394,"type":22},"2028-10-01",{"name":68,"class":41},{"id":397,"slug":398,"hasResults":11,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":4,"eligibilityCriteria":402,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":403,"targetDuration":4,"studyType":23,"phases":404,"briefSummary":405,"conditions":406,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":314},"100569860","impact-of-mindful-self-compassion-therapy-on-self-harm-behaviors-emotional-regulation-and-quality-of-life-among-patients-with-borderline-personality-disorder-100569860","NCT06699732","Impact of Mindful Self-Compassion Therapy on Self Harm Behaviors, Emotional Regulation and Quality of Life Among Patients With Borderline Personality Disorder","Impact of Mindful Self-Compassion Therapy on Self Harm Behaviors, Emotional Regulation and Quality of Life Among Patients With Borderline Personality Disorder: A Randomized Controlled Trial","Inclusion Criteria:\n\n* 1\\. First time diagnosed non-hospitalized patients of Borderline Personality Disorder.\n\n  2\\. Patients of Borderline Personality Disorder experiencing psychological distress,low level of quality of life, social support, emotional dysregulation would be included.\n\n  3\\. Borderline Personality Disorder patients with age 18 years and above (both gender) from outpatient department (OPD) 4. Borderline personality patients who would be able to understand Urdu language and can give the informed consent\n* Exclusion criteria\n\nThe study would have the following exclusion criteria:\n\n1. Hospitalized patients of Borderline Personality\n2. Patients with Borderline Personality having other chronic co-morbid diseases such as cancer, cognitive deficits, and other chronic psychological disorders.\n3. Patients with Borderline Personality younger than 18 years of age",{"count":287,"type":22},[25],"The primary purpose of the study is to investigate whether Mindful Self-Compassion (MSC) therapy can significantly reduce self-harm behaviors, improve emotional regulation, and enhance the quality of life in individuals diagnosed with Borderline Personality Disorder (BPD). The study aims to contribute to the existing literature by providing robust evidence on the efficacy of MSC therapy for BPD, which could inform clinical practices and improve treatment outcomes",[407,408,353,409,28],"Psychological Distress","Emotional Regulation","Quality of Life (QOL)","2025-08-29",{"date":412,"type":34},"2025-09-02",{"date":414,"type":34},"2024-09-21",{"date":416,"type":22},"2025-12-30",{"name":418,"class":41},"Fatima Jinnah Women University",{"id":420,"slug":421,"hasResults":11,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":425,"eligibilityCriteria":426,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":427,"targetDuration":4,"studyType":23,"phases":429,"briefSummary":430,"conditions":431,"keywords":4,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":4},"100581270","study-of-emotional-dysregulation-in-complex-post-traumatic-stress-disorder-100581270","NCT06848127","Study of Emotional Dysregulation in Complex Post-Traumatic Stress Disorder","At the Frontier of Post-Traumatic Stress Disorder and Borderline Personality Disorder: Characterization Complex Post-traumatic Stress Disorder Via an Ecological, Physiological and Cognitive Approach to the Emotional Dysregulation","TR-EMA","Inclusion Criteria:\n\n* Inclusion criteria common to healthy patients and volunteers: Subject, male or female, over 18 years of age; Subject able to understand the objectives and risks of the research and to give informed, dated and signed consent; Subject affiliated to a social protection health insurance scheme, beneficiary or beneficiary.\n* Patient-specific inclusion criteria: Patient with a diagnosis of PTSD or PTSD according to ICD-11 criteria (World Health Organization, 2018). OR Patient with a diagnosis of BPD, according to DSM-5 criteria (American Psychiatric Association, 2013). OR Patient with cPTSD + BPD comorbidity, established prior to inclusion.\n* Inclusion criteria specific to healthy volunteers: Subject who has been exposed to a traumatic event (Life Events Checklist, Gray et al., 2004) but without traumatic symptoms, or has subcut-off scores on PTSD scales (PCL-5, PTSD Checklist for DSM-5, Blevins et al., 2015), and TPB (BSL-23, Borderline Symptom List, Nicastro et al., 2016).\n\nExclusion Criteria:\n\n* Non-inclusion criteria common to healthy patients and volunteers:\n\nSubject who does not have a smartphone with an internet connection; Subject in an exclusion period (determined by a previous or ongoing study); Participation in another clinical study that may interfere with the study; Inability to provide the subject with informed information (subject in an emergency or life-threatening situation); Subject under the protection of justice; Subject under guardianship or curatorship; Pregnancy and\u002For breastfeeding.\n\n-Patient-specific non-inclusion criteria: Patient with a diagnosis of a psychotic disorder (according to DSM-5 criteria, American Psychiatric Association, 2013); Patient with a diagnosis of severe substance use disorder (according to DSM-5 criteria, American Psychiatric Association, 2013); Patient with an intellectual disability (IQ ≤ 70); Patient with neurological (acquired brain injury) or neurovegetative comorbidity; Patient following or having undergone psychotherapy of the Dialectical Behavior Therapy (DBT) type; Patient with severe cardiac disorders; Patient on therapy that alters physiological response (e.g., beta-blockers).\n\n-Specific non-inclusion criteria for healthy volunteers: Subject with a history of psychiatric, neurodevelopmental, neurological, neurovegetative or cardiac disorders; Subject on psychotropic therapy or treatment modifying physiological parameters (e.g., beta-blockers).",{"count":428,"type":22},170,[25],"This study aims to characterize emotional dysregulation in complex post-traumatic stress disorder (cPTSD) and to determine the extent to which it can promote the distinction with borderline personality disorder (BPD) and post-traumatic stress disorder (PTSD).\n\nAs emotional dysregulation is a dynamic process whose phenomenological manifestations are labile, associated with physiological modifications and modulated by cognitive processing, a multiple methodology associating measurements in a real-life ecological context with measurements performed in the hospital will be preferred.\n\nOverall, this study proposes to capture, for the first time, the clinical manifestations associated with cPTSD from the perspective of emotional dysregulation and its underlying processes",[432,28,433],"Complex Post-Traumatic Stress Disorder (CPTSD)","Post-traumatic Stress Disorder (PTSD)","2025-02-20",{"date":436,"type":34},"2025-02-26",{"date":438,"type":22},"2025-03-01",{"date":440,"type":22},"2027-12-01",{"name":146,"class":41},{"id":443,"slug":444,"hasResults":11,"nctId":445,"briefTitle":446,"officialTitle":447,"acronym":4,"eligibilityCriteria":448,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":449,"targetDuration":4,"studyType":23,"phases":450,"briefSummary":451,"conditions":452,"keywords":453,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":459,"lastUpdatePostDateStruct":460,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":466,"locationsCount":42},"100531112","application-and-effectiveness-of-the-stepps-in-patients-with-bpd-extending-to-their-families-with-the-fc-program-100531112","NCT06195553","Application and Effectiveness of the STEPPS in Patients with BPD, Extending to Their Families with the FC Program","Application and Analysis of the Effectiveness of the STEPPS Program in Patients with BPD, Extending to Their Families with the Family Connections Program: a Randomized Controlled Trial","PATIENTS\n\nInclusion Criteria:\n\n* Being at least 18 years old.\n* Be a patients with symptoms compatible with a diagnosis of BPD who is undergoing treatment or follow-up in someone of the indicated recruitment centers.\n* Sign an informed consent.\n\nExclusion Criteria:\n\n* The presence of any pathology that prevents carrying out the intervention: major depression, psychosis, schizophrenia, substance dependence, eating disorders, another personality disorder, borderline IQ, etc., which due to its severity is currently interfering.\n\nFAMILIES:\n\nInclusion Criteria:\n\n* Being at least 18 years old.\n* Be a relative of someone of the patients with symptoms compatible with a diagnosis of BPD who is undergoing treatment or follow-up in someone of the indicated recruitment centers.\n* Sign an informed consent.\n\nExclusion Criteria:\n\n* The presence of any pathology that prevents carrying out the intervention: major depression, psychosis, schizophrenia, substance dependence, eating disorders, another personality disorder, borderline IQ, etc., which due to its severity is currently interfering.",{"count":208,"type":22},[25],"The present research project is framed within the issue of Borderline Personality Disorder (BPD). This condition stands as one of the most common challenges encountered within the mental health services of the National Health System. The primary objectives of this research are to verify whether the combined use of established treatments for patients and their families, conducted in parallel, leads to a greater improvement in patients and their families, respectively. Additionally, another aim of the project is to assess efficiency, defined as the acceptance of intervention programs by patients, their families, and clinical professionals, as well as to demonstrate their feasibility.",[28],[454,58,455,456,457,458,303],"Personality disorder","stepps","family connections","family focused therapy","family involvement","2025-01-13",{"date":461,"type":34},"2025-01-15",{"date":463,"type":34},"2024-01-02",{"date":465,"type":22},"2026-07-01",{"name":467,"class":41},"Universitat Jaume I"]